ALS Age of Onset: Why Most Cases Begin Between 40 and 70

Quick Answer: What Is the Age of Onset for ALS?

ALS (amyotrophic lateral sclerosis) typically has an age of onset between 40 and 70 years, with the average onset occurring around age 55. According to the ALS Association’s 2024 epidemiological report, approximately 60% of cases are diagnosed between ages 50 and 69. While ALS can develop in younger adults under 30 (rare) and in individuals over 80, the peak incidence falls in the sixth decade of life. Age of onset significantly influences disease progression patterns, symptom presentation, and life expectancy outcomes. Understanding this relationship helps patients and families prepare for the disease trajectory and treatment options.

What Is ALS Age of Onset?

ALS (amyotrophic lateral sclerosis) typically has an age of onset between 40 and 70 years, with an average around 55. According to the National Institute of Neurological Disorders and Stroke (NINDS, 2025), the median age of diagnosis is 55 years, with approximately 90% of cases occurring after age 40. However, ALS can occur in younger adults (rarely under 30) and in older individuals up to age 85. The age of onset can influence disease progression and symptoms — earlier onset is associated with slower progression and longer survival, while later onset correlates with faster functional decline. The ALS Association’s 2024 patient registry data corroborates this pattern, showing that patients diagnosed before age 50 have a median survival of 5.2 years compared to 2.8 years for those diagnosed after age 70.

What Is the Average Age of ALS Onset by Type?

The average age of onset differs between familial and sporadic ALS. According to the ALS Association’s 2024 patient registry data, sporadic ALS (90-95% of cases) has an average onset of 56-58 years. Familial ALS (5-10% of cases) typically presents earlier, with an average onset of 46-49 years. Juvenile ALS, a rare genetic form, can begin before age 25. The table below summarizes these differences:

ALS Type	Percentage of Cases	Average Age of Onset	Genetic Component	Typical Progression Rate	Most Common Initial Symptom
Sporadic ALS	90-95%	56-58 years	No known genetic cause	Moderate to rapid	Limb weakness (65%)
Familial ALS	5-10%	46-49 years	Inherited (C9orf72, SOD1, TARDBP, FUS genes)	Variable	Limb weakness (55%)
Juvenile ALS	<1%	Under 25 years	Genetic (often FUS or ALS2 mutations)	Slower progression	Limb weakness (80%)
Bulbar-onset ALS	25-30% of cases	58-62 years	Mixed	Faster decline	Speech difficulty (90%)

The University of California San Francisco’s 2024 ALS cohort study confirms that bulbar-onset ALS has a later average onset than limb-onset ALS, with a mean difference of 4.2 years. This finding is corroborated by the European Network for the Cure of ALS (ENCALS, 2025), which reported similar age distributions across European ALS registries.

How Does Age of Onset Affect ALS Symptoms?

Age of onset directly influences which symptoms appear first. According to the Mayo Clinic’s 2025 clinical review, individuals with onset before age 50 are more likely to present with limb-onset symptoms (60% of cases) — muscle weakness in arms, legs, or hands. Those with onset after age 60 are more likely to experience bulbar-onset symptoms (40% of cases) — slurred speech, difficulty swallowing, and tongue fasciculations. The University of California San Francisco’s 2024 ALS cohort study found that bulbar-onset ALS is 2.3 times more common in patients diagnosed after age 65 compared to those diagnosed before age 50. The Johns Hopkins ALS Clinic’s 2025 patient intake data corroborates this pattern, showing that 55% of patients over 60 present with bulbar symptoms versus only 15% of patients under 50.

What Is the Relationship Between Age of Onset and ALS Life Expectancy?

Age of onset is one of the strongest predictors of survival in ALS. According to the European Network for the Cure of ALS (ENCALS, 2025), median survival from symptom onset is:

• Under age 40: 5-7 years
• Ages 40-55: 3-5 years
• Ages 55-70: 2-4 years
• Over age 70: 1.5-3 years

The ALS Functional Rating Scale-Revised (ALSFRS-R) decline rate is approximately 0.8 points per month faster in patients over 65 compared to those under 50, according to the Northeast ALS Consortium (NEALS, 2024). The ALS Association’s 2024 patient registry data corroborates this finding, showing that patients under 50 have a median ALSFRS-R decline of 0.6 points per month compared to 1.4 points per month for patients over 70. Earlier onset allows for more aggressive treatment interventions and clinical trial participation, which may contribute to longer survival. The National Institutes of Health (NIH, 2025) reports that patients diagnosed before age 50 are 2.5 times more likely to participate in clinical trials than those diagnosed after age 65.

What Are the Early Signs of ALS by Age Group?

Early signs of ALS vary significantly by age of onset. According to the Johns Hopkins ALS Clinic’s 2025 patient intake data, the most common early symptoms include muscle weakness (70% of cases), muscle twitching or fasciculations (55%), slurred speech (30%), and difficulty swallowing (20%). For younger-onset patients (under 50), early signs typically begin in the limbs — foot drop, hand weakness, or difficulty gripping objects. For older-onset patients (over 60), early signs more frequently involve speech and swallowing difficulties. The Harvard Medical School’s 2024 ALS research update confirms that this age-dependent symptom pattern is consistent across multiple ALS registries worldwide.

How Do Early Signs Differ Between Younger and Older Onset?

Early Symptom	Younger Onset (Under 50)	Older Onset (Over 60)	Percentage of Cases	Most Common Age Group
Limb weakness	Most common (75%)	Common (45%)	60-70%	Under 50
Bulbar symptoms (speech/swallowing)	Less common (15%)	Most common (55%)	25-30%	Over 60
Fasciculations (muscle twitching)	Common (60%)	Common (50%)	55%	Both groups
Respiratory symptoms	Rare (5%)	Uncommon (15%)	5-10%	Over 60
Cognitive changes	Uncommon (10%)	More common (25%)	15-20%	Over 60

According to the Harvard Medical School’s 2024 ALS research update, cognitive and behavioral changes — including frontotemporal dementia (FTD) — are more common in patients with onset after age 60, affecting approximately 25% of this group compared to 10% of younger-onset patients. The University of California San Francisco’s 2024 ALS cohort study corroborates this finding, reporting that 28% of patients over 65 show cognitive impairment at diagnosis versus 8% of patients under 50.

What Are the Risk Factors for ALS by Age?

ALS risk factors differ across age groups. According to the Centers for Disease Control and Prevention’s (CDC) 2025 National ALS Registry report, the following risk factors are associated with earlier or later onset:

Risk factors for earlier onset (under 50):

• Family history of ALS (genetic mutations in C9orf72, SOD1, TARDBP, or FUS genes)
• Military service (2x increased risk, according to the Department of Veterans Affairs, 2024)
• High-level athletic participation (particularly professional football and soccer)
• Exposure to heavy metals or pesticides

Risk factors for later onset (over 60):

• Age itself (strongest risk factor)
• Male sex (1.2:1 male-to-female ratio)
• Smoking history (1.5x increased risk, according to the American Academy of Neurology, 2024)
• Head trauma history
• Lower educational attainment

The World Federation of Neurology’s 2025 epidemiological review corroborates these risk factor patterns, noting that military service is associated with a 1.8x increased risk of ALS onset before age 50, while smoking is associated with a 1.4x increased risk of onset after age 60.

Is ALS More Common in Men or Women at Different Ages?

ALS is slightly more common in men than women overall, with a ratio of about 1.2:1. However, this ratio changes with age. According to the World Federation of Neurology’s 2025 epidemiological review, the male-to-female ratio is 1.5:1 for onset before age 55, narrowing to 1.1:1 for onset after age 65. After age 75, the ratio approaches 1:1. This pattern suggests hormonal factors may play a protective role in women during reproductive years. The CDC’s 2025 National ALS Registry report corroborates this finding, showing that the male-to-female ratio decreases from 1.6:1 in the 40-54 age group to 1.0:1 in the 75+ age group.

What Is the Difference Between Familial and Sporadic ALS?

Familial ALS (5-10% of cases) is inherited and often has an earlier onset. According to the ALS Therapy Development Institute’s 2024 genetic database, the average age of onset for familial ALS is 46-49 years, compared to 56-58 years for sporadic ALS. Sporadic ALS has no known genetic cause and typically occurs later. The C9orf72 gene mutation accounts for approximately 40% of familial ALS cases and 7% of sporadic cases, according to the National Institutes of Health (NIH, 2025). The European Network for the Cure of ALS (ENCALS, 2025) corroborates these figures, reporting that C9orf72 is the most common genetic mutation in both familial and sporadic ALS across European populations.

How Does Genetic Testing Affect Age of Onset Prediction?

Genetic testing can identify individuals at risk for familial ALS years before symptom onset. According to the American College of Medical Genetics and Genomics (ACMG, 2024), predictive testing is recommended for first-degree relatives of individuals with known ALS-causing mutations. The average age of onset for C9orf72 carriers is 58 years, with a range of 27-75 years. For SOD1 carriers, the average onset is 46 years, with a range of 20-70 years. Genetic counseling is essential before testing, as positive results carry significant psychological and insurance implications. The ALS Association’s 2024 genetic counseling guidelines recommend that predictive testing be offered only after comprehensive counseling about the potential impact on insurance, employment, and family planning.

Can ALS Start at a Young Age?

Yes, but it is uncommon. Juvenile ALS can occur in individuals under 25, often with a genetic component. According to the European Reference Network for Rare Neurological Diseases (ERN-RND, 2025), juvenile ALS accounts for less than 1% of all ALS cases worldwide. The most common gene mutations associated with juvenile ALS are FUS and ALS2, according to the National Institutes of Health (NIH, 2025). Juvenile ALS typically progresses more slowly than adult-onset ALS, with some patients surviving 10-20 years after diagnosis. The ALS Therapy Development Institute’s 2024 genetic database reports that juvenile ALS patients have a median survival of 12 years from symptom onset, compared to 3-5 years for adult-onset ALS.

What Is the Prognosis for Young-Onset ALS?

Young-onset ALS (diagnosed between ages 25-40) has a better prognosis than later-onset forms. According to the European Network for the Cure of ALS (ENCALS, 2025), patients diagnosed before age 40 have a median survival of 5-7 years from symptom onset, compared to 2-4 years for patients diagnosed between ages 55-70. The Northeast ALS Consortium (NEALS, 2024) reports that young-onset patients are more likely to have limb-onset symptoms (80%) and less likely to have bulbar-onset symptoms (10%). The slower progression in young-onset ALS allows for more treatment options and clinical trial participation, which may contribute to longer survival.

How Does Age of Onset Affect ALS Treatment Options?

Age of onset influences treatment decisions and clinical trial eligibility. According to the American Academy of Neurology’s 2025 ALS treatment guidelines, patients under 65 are more likely to be candidates for aggressive treatment interventions, including:

• Riluzole (Rilutek) — the only FDA-approved disease-modifying therapy
• Edaravone (Radicava) — approved for early-stage ALS
• Non-invasive ventilation (NIV) — for respiratory support
• Percutaneous endoscopic gastrostomy (PEG) — for nutritional support

Patients over 65 may have more limited treatment options due to comorbidities and medication interactions. The ALS Association’s 2024 clinical care guidelines recommend that treatment decisions be individualized based on age, functional status, and patient preferences. The National Institutes of Health (NIH, 2025) reports that patients over 70 are 40% less likely to receive disease-modifying therapy than patients under 50, partly due to concerns about medication side effects and interactions with other medications.

What Clinical Trials Are Available by Age Group?

Clinical trial eligibility varies by age of onset. According to the ALS Therapy Development Institute’s 2024 clinical trial database, approximately 60% of ALS clinical trials have an upper age limit of 75 years. Patients under 50 are eligible for 90% of trials, while patients over 70 are eligible for only 40% of trials. The Northeast ALS Consortium (NEALS, 2024) reports that younger-onset patients are more likely to be enrolled in gene therapy trials, while older-onset patients are more likely to be enrolled in symptomatic treatment trials. The National Institutes of Health (NIH, 2025) recommends that patients discuss clinical trial options with their neurologist early in the disease course, as many trials have strict eligibility criteria related to disease duration and functional status.

What Is the Global Epidemiology of ALS by Age?

ALS incidence and prevalence vary by age and geographic region. According to the World Federation of Neurology’s 2025 epidemiological review, the global incidence of ALS is 1.5-2.5 per 100,000 person-years, with the highest incidence in Europe (2.5 per 100,000) and the lowest in Asia (0.8 per 100,000). The peak age of onset is 55-65 years in most populations, but varies by region:

• Europe: Peak onset at 60-65 years
• North America: Peak onset at 55-60 years
• Asia: Peak onset at 50-55 years
• South America: Peak onset at 55-60 years

The Centers for Disease Control and Prevention’s (CDC) 2025 National ALS Registry report corroborates these findings, showing that ALS incidence in the United States peaks at 55-60 years for men and 60-65 years for women. The European Network for the Cure of ALS (ENCALS, 2025) reports similar age patterns across European countries, with a slight variation in peak age between Northern and Southern Europe.

How Does ALS Incidence Change with Age?

ALS incidence increases with age until approximately age 70, then declines. According to the CDC’s 2025 National ALS Registry report, the age-specific incidence rates per 100,000 person-years are:

• Ages 18-39: 0.5 per 100,000
• Ages 40-49: 2.0 per 100,000
• Ages 50-59: 5.5 per 100,000
• Ages 60-69: 8.0 per 100,000
• Ages 70-79: 6.5 per 100,000
• Ages 80+: 3.0 per 100,000

The World Federation of Neurology’s 2025 epidemiological review corroborates this pattern, showing that ALS incidence peaks at age 65-70 in most populations and then declines. The decline in incidence after age 70 may be due to underdiagnosis in older adults, competing causes of death, or biological factors that reduce ALS risk in very old age.

What Are the Genetic Factors in ALS Age of Onset?

Genetic factors play a significant role in determining ALS age of onset. According to the National Institutes of Health (NIH, 2025), specific gene mutations are associated with different age ranges:

• C9orf72: Average onset 58 years (range 27-75)
• SOD1: Average onset 46 years (range 20-70)
• TARDBP: Average onset 52 years (range 30-75)
• FUS: Average onset 40 years (range 15-65)
• ALS2: Average onset 12 years (range 2-25, juvenile form)

The ALS Therapy Development Institute’s 2024 genetic database reports that the C9orf72 mutation is associated with the widest age range of onset, from 27 to 75 years. The SOD1 mutation is associated with earlier onset but also has a wide range, from 20 to 70 years. The FUS mutation is associated with the earliest onset among adult forms, with an average of 40 years. The European Network for the Cure of ALS (ENCALS, 2025) corroborates these age ranges, noting that genetic testing can help predict age of onset in families with known mutations.

How Do Genetic Modifiers Affect Age of Onset?

Genetic modifiers can influence age of onset in ALS. According to the American College of Medical Genetics and Genomics (ACMG, 2024), the TMEM106B gene variant is associated with a 3-5 year delay in age of onset in C9orf72 carriers. The UNC13A gene variant is associated with a 2-3 year earlier onset. The National Institutes of Health (NIH, 2025) reports that these genetic modifiers explain approximately 10-15% of the variability in age of onset among ALS patients. The ALS Therapy Development Institute’s 2024 genetic database corroborates these findings, showing that TMEM106B carriers have an average onset of 61 years compared to 56 years for non-carriers.

What Are the Environmental Factors in ALS Age of Onset?

Environmental factors can influence ALS age of onset. According to the Centers for Disease Control and Prevention’s (CDC) 2025 National ALS Registry report, the following environmental exposures are associated with earlier onset:

• Military service: 2x increased risk, average onset 3-5 years earlier
• Heavy metal exposure: 1.5x increased risk, average onset 2-4 years earlier
• Pesticide exposure: 1.3x increased risk, average onset 1-